login
Password reminder
Cardiac Rhythm News
Contact the editor Visit Cardiac Rhythm News Twitter feed Visit Cardiac Rhythm News Facebook page
 

New renal impairment data from ROCKET AF study of rivaroxaban shows outcomes consistent with primary analysis


Tuesday, 30 Aug 2011 09:51



Findings from a key sub-analysis of the global phase III ROCKET AF study of patients with atrial fibrillation (AF) and moderate renal impairment demonstrate results in line with the study’s primary efficacy and safety analysis. 


The data presented at the European Society of Cardiology (ESC) by Keith Fox, co-chair of the ROCKET AF Executive Steering Committee and professor of Cardiology at the University of Edinburgh, show that these patients respond favourably to a reduced 15mg daily dose of Bayer’s Xarelto (rivaroxaban) compared with warfarin, an outcome consistent with those with preserved renal function who were given 20mg of rivaroxaban daily.


The use of traditional anticoagulants such as vitamin K antagonists (VKAs) including warfarin in patients with AF and renal impairment can be challenging for physicians, due to the need for regular dosing changes to avoid complications such as over-anticoagulation which can lead to major bleeding events. 

 

In this sub-group of 2,950 patients (representing 21% of the overall study population), rivaroxaban showed comparable safety outcomes to warfarin; importantly, rates of critical organ bleeding (HR 0.55; 95% CI 0.30-1.00) and fatal bleeding (HR 0.55; 95% CI 0.32-0.93) were lower with rivaroxaban, consistent with results seen by investigators in the ROCKET AF primary analysis. Gastrointestinal bleeding was more frequent in the rivaroxaban group compared to warfarin (4.1% vs. 2.6%, p=0.02). There were no significant differences in other bleeding sites between rivaroxaban 15mg and dose-adjusted warfarin.


The primary efficacy endpoint rate (incidence of stroke or non-central nervous systemic embolism) was 2.32 events per 100 patient years with rivaroxaban 15mg per day, compared with 2.77 events per 100 patient years with dose-adjusted warfarin  in the per-protocol population (HR 0.84; 95% CI 0.57-1.23, p value for interaction=0.76).


Together, these efficacy and safety findings confirm the primary results of ROCKET AF study published by the New England Journal of Medicine (NEJM) in August 2011.


The mean age of enrolled patients in ROCKET AF with moderate renal dysfunction was 79, older than the mean age of 73 in patients without renal dysfunction who received a higher 20mg dose of rivaroxaban.


“The findings of this analysis demonstrate that rivaroxaban has the ability to prevent stroke in patients with moderate renal insufficiency, without elevating the risk of critical bleeding events such as intra-cranial haemorrhage,” said Fox. “The average age of 79 in this group is also important, because patients with non-valvular AF tend to be of older age, and can have a higher risk of stroke due to the increased prevalence of conditions like congestive heart failure, hypertension, diabetes and prior stroke.”


Rivaroxaban is currently licensed in the UK for the prevention of venous thromboembolism (VTE) in patients undergoing elective total hip or knee replacement surgery, and is not licensed for the prevention of stroke and non-CNS systemic embolism in patients with non-valvular AF. 




Add New Comment

Related Items


Most popular


New ultrasound-based system shows promise mapping atrial fibrillation
Wednesday, 06 Jan 2016
Initial findings have shown that a new ultrasound-based imaging system with continuous dipole density mapping provides real-time rapid global left atrial reconstruction and compares favourably to ... New ultrasound-based system shows promise mapping atrial fibrillation

US cardiovascular societies publish joint expert consensus on left atrial appendage occlusion requirements
Friday, 11 Dec 2015
SCAI, ACC, and HRS have published a joint document providing recommendations for the establishment and maintenance of left atrial appendage occlusion programmes performing LAA closure. US cardiovascular societies publish joint expert consensus on left atrial appendage occlusion requirements

Bridge occlusion balloon submitted for FDA 510(k) Premarket Notification for lead extraction procedures
Wednesday, 09 Dec 2015
The device from Spectranetics is designed to substantially reduce blood loss in the event of a superior vena cava tear. Bridge occlusion balloon submitted for FDA 510(k) Premarket Notification for lead extraction procedures

Features


Has leadless pacing changed practice?
Monday, 18 Jan 2016
Chu-Pak Lau explores the development and use of externally-powered and entirely intracardiac leadless pacemakers, and considers the effect they have had on clinical practice. Has leadless pacing changed practice?

In the absence of testing, ICD optimisation should always be done
Friday, 08 Jan 2016
Mark W Kroll (Minneapolis, USA) writes about the importance of optimisation of implantable cardioverter defibrillators (ICDs) in the absence of defibrillation threshold testing. In the absence of testing, ICD optimisation should always be done

Profiles


Jonathan Kalman
Monday, 18 Jan 2016
A leading heart rhythm expert in Australia, Jonathan M Kalman directs both clinical and research ... Jonathan Kalman

Michael Glikson
Wednesday, 14 Oct 2015
Michael Glikson (Tel Hashomer, Israel) has contributed to the development of technologies for CRT, ... Michael Glikson

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions